Literature DB >> 1826650

Immune complex binding efficiency of erythrocyte complement receptor 1 (CR1).

N Madi1, J P Paccaud, G Steiger, J A Schifferli.   

Abstract

C3b-coated immune complexes adhere to the complement receptor 1 (CR1, CD35) on human erythrocytes. This multi-valent binding might be favoured by the known clustering of CR1 and by the multiple C3b-binding sites on each CR1. The size of the CR1 clusters correlates directly with the number of CR1/erythrocytes, and the different structural CR1 alleles bear between two and five C3b-binding sites. Using radiolabelled hepatitis B surface antigen-antibody complexes, we investigated whether CR1 numbers and structural alleles modulate the ability of erythrocytes to bind immune complexes, and assessed if any reorganization of immune complexes takes place at the erythrocyte surface after the initial binding reaction. The binding efficiency (immune complexes/CR1) correlated with CR1 number as determined by the maximal binding at 4 degrees C, the kinetics of binding at 37 degrees C, and the binding in the presence of excess immune complexes and of immune complexes of small size. Binding efficiencies were similar for erythrocytes with low CR1 from normal subjects and patients with AIDS or SLE. A monoclonal antibody blocking the C3b-binding sites (3D9) of CR1 interfered with binding efficiency at a lower concentration on cells bearing low CR1 numbers, suggesting that CR1 clustering is essential. The larger alleles of CR1 (DD and BB) were more efficient than AA alleles. The distribution of immune complexes, visualized by immunofluorescence, was heterogeneous on erythrocytes: about two out of three cells bore between one and 12 immune complexes. No visible immune complex reorganization took place after initial binding, as prefixed erythrocytes displayed the same immune complex distribution and number/erythrocytes as unfixed erythrocytes. The contribution of CR1 alleles in immune complex binding efficiency was confirmed by morphological analysis. These results demonstrate that immune adherence efficiency is the resultant of the CR1 clustering, as well as the particular alleles carried by erythrocytes. Moreover, there is little or no immune complexes surface reorganization after the initial binding reaction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826650      PMCID: PMC1535347          DOI: 10.1111/j.1365-2249.1991.tb08116.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis.

Authors:  R A NELSON
Journal:  Science       Date:  1953-12-18       Impact factor: 47.728

2.  The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms.

Authors:  J A Schifferli; Y C Ng; J Estreicher; M J Walport
Journal:  J Immunol       Date:  1988-02-01       Impact factor: 5.422

3.  Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions.

Authors:  Y C Ng; J A Schifferli; M J Walport
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

4.  Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes.

Authors:  J C Edberg; L Tosic; E L Wright; W M Sutherland; R P Taylor
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

5.  Size polymorphism of the erythrocyte complement receptor type 1 (CR1) in systemic lupus erythematosus induced by hydralazine.

Authors:  J A Mitchell; E Sim
Journal:  Complement Inflamm       Date:  1989

6.  Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.

Authors:  G D Ross; W J Yount; M J Walport; J B Winfield; C J Parker; C R Fuller; R P Taylor; B L Myones; P J Lachmann
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

7.  The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans.

Authors:  J A Schifferli; Y C Ng; J P Paccaud; M J Walport
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

8.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

9.  Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome.

Authors:  F A Tausk; A McCutchan; P Spechko; R D Schreiber; I Gigli
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

10.  Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele.

Authors:  W W Wong; J M Cahill; M D Rosen; C A Kennedy; E T Bonaccio; M J Morris; J G Wilson; L B Klickstein; D T Fearon
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  8 in total

1.  Soluble form of complement C3b/C4b receptor (CR1) results from a proteolytic cleavage in the C-terminal region of CR1 transmembrane domain.

Authors:  I Hamer; J P Paccaud; D Belin; C Maeder; J L Carpentier
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

2.  The role of complement receptor type 1 (CR1, CD35) in determining the cellular distribution of opsonized immune complexes between whole blood cells: kinetic analysis of the buffering capacity of erythrocytes.

Authors:  C H Nielsen; S H Matthiesen; I Lyng; R G Leslie
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

Review 3.  Complement deficiency and immune complex disease.

Authors:  K A Davies; J A Schifferli; M J Walport
Journal:  Springer Semin Immunopathol       Date:  1994

4.  Both Fcgamma and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions in vitro.

Authors:  A L Hepburn; J C Mason; S Wang; C J Shepherd; O Florey; D O Haskard; K A Davies
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

5.  Ligation of erythrocyte CR1 induces its clustering in complex with scaffolding protein FAP-1.

Authors:  Ionita Ghiran; Aleksandra M Glodek; Gregory Weaver; Lloyd B Klickstein; Anne Nicholson-Weller
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

6.  Soluble complement receptor type 1 (sCR1) in chronic liver diseases: serum levels at different stages of liver diseases.

Authors:  D Di Bona; G Montalto; L Clemenza; F Bascone; P Accardo; D Bellavia; A Craxì; M Brai
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

7.  Reduced immune complex binding capacity and increased complement susceptibility of red cells from children with severe malaria-associated anemia.

Authors:  Boaz O Owuor; Collins O Odhiambo; Walter O Otieno; Christine Adhiambo; Dominic W Makawiti; José A Stoute
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

8.  Increased deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic region of western Kenya: implications for the development of severe anemia.

Authors:  Collins O Odhiambo; Walter Otieno; Christine Adhiambo; Michael M Odera; José A Stoute
Journal:  BMC Med       Date:  2008-08-21       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.